Only the gene body of MGMT showed a low level of methylation increase in CDKN2A-mutated patients compared to sporadic melanoma patients (2% increase in the methylation level, P = 0.02, Supplementary Table 3). The gene discussed is CDKN2A; the disease is melanoma.